| ²é¿´: 2865 | »Ø¸´: 8 | |||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||
yanzhang722ľ³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú¶÷Ìæ¿¨Î¤ÔÁÏÒ©Àí»¯ÐÔÖÊ
|
||
| È۵㡢±ÈÐý¹â¶È¡¢ÈܽâÐÔ¡¢pka£¬½âÀë³£ÊýµÈ |
» ²ÂÄãϲ»¶
ҩѧѧ˶326Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
105500ҩѧµ÷¼Á£¬Ò»Ö¾Ô¸¶¥9£¬Ö÷³ÖÊ¡¼¶´ó´´£¬ÊµÑéÐÍSCI¶þ×÷£¬ËÄÁù¼¶Òѹý£¬Ë«¹ú½±
ÒѾÓÐ6È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ160È˻ظ´
ҩѧר˶µ÷¼Á
ÒѾÓÐ0È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ0È˻ظ´
publcifµÄʹÓÃ
ÒѾÓÐ0È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ1È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
»á¼Æ×¨Ë¶Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ҩѧר˶É격
ÒѾÓÐ1È˻ظ´
ÐÂ¼ÓÆÂ¹úÁ¢´óѧҩѧϵ»¯Ñ§ÉúÎïѧ¿ÎÌâ×éÕÐPhD
ÒѾÓÐ12È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
:)´ó¼ÒºÃ£¬ÎÒÊÇÐÂÊÖ£¬ÎÒÏëÇë½Ìϸ÷λÈçºÎ²éѯһÖÖ»¯Ñ§ÔÁÏÒ©µÄÀí»¯ÐÔÖÊ£¿
ÒѾÓÐ9È˻ظ´
ÇóÖú¹ØÓÚ»¯ºÏÎïÀí»¯ÐÔÖʲéѯµÄÍøÕ¾ºÍÊý¾Ý¿â
ÒѾÓÐ9È˻ظ´
¡¾Ô´´¡¿×ªÈö÷Ìæ¿¨Î¤¡¢ÄªÎ÷ɳÐÇ¡¢ÒÁÂíÌæÄáµÈ¶àÖÖÔÁÏÒ©¹¤ÒÕ£¨º¬¸÷ÖÖ±ê×¼£©£¬·Ç³ÏÎðÈÅ
ÒѾÓÐ6È˻ظ´
¡¾ÇóÖú¡¿³¤´ºÎ÷Í¡ÔÁÏÒ©
ÒѾÓÐ14È˻ظ´
¡¾ÇóÖú¡¿¦Á-Ï㸽ͪµÄÀí»¯ÐÔÖʵȷ½ÃæµÄÑо¿
ÒѾÓÐ4È˻ظ´
¡¾ÇóÖú¡¿ÔÁÏÒ©ËáÆÆ»µºÍ¼îÆÆ»µÊµÑéµÄÁ½¸ö¸öÎÊÌâ
ÒѾÓÐ32È˻ظ´
¡¾ÇóÖú¡¿¹ØÓÚÉú²úµÄÔÁÏÒ©µÄȱ·¦ÎÊÌâ
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú¡¿ÔõÃ´ÍÆ¶ÏÓлúÎïµÄÀí»¯ÐÔÖÊ
ÒѾÓÐ11È˻ظ´
¡¾ÇóÖú¡¿ÇëÎÊ180#ÈܼÁÓÍÀí»¯ÐÔÖÊ£¿
ÒѾÓÐ4È˻ظ´
³ÕÒÄ×ÓÆ¤
°æÖ÷ (ÎÄ̳¾«Ó¢)
ÀÏÆ¦
- DRDEPI: 8
- Ó¦Öú: 2016 (½²Ê¦)
- ¹ó±ö: 5.368
- ½ð±Ò: 54487.3
- É¢½ð: 41688
- ºì»¨: 303
- ɳ·¢: 1206
- Ìû×Ó: 32611
- ÔÚÏß: 4303.7Сʱ
- ³æºÅ: 674536
- ×¢²á: 2008-12-14
- ÐÔ±ð: GG
- רҵ: ÎÞÉñÂÛ
- ¹ÜϽ: ÈËÎÄÉç¿Æ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
lk590(½ð±Ò+3): лл²ÎÓë 2012-02-21 13:23:00
yanzhang722(½ð±Ò+5): ¡ïÓаïÖú 2012-02-24 08:43:18
lk590(½ð±Ò+3): лл²ÎÓë 2012-02-21 13:23:00
yanzhang722(½ð±Ò+5): ¡ïÓаïÖú 2012-02-24 08:43:18
|
Title: Entecavir CAS Registry Number: 142217-69-4 CAS Name: 2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one Molecular Formula: C12H15N5O3 Molecular Weight: 277.28 Percent Composition: C 51.98%, H 5.45%, N 25.26%, O 17.31% Literature References: Deoxyguanine nucleoside analog; inhibits hepatitis B virus (HBV) DNA polymerase. Prepn: R. Zahler, W. A. Slusarchyk, EP 481754; eidem, US 5206244 (1992, 1993 both to Squibb); G. S. Bisacchi et al., Bioorg. Med. Chem. Lett. 7, 127 (1997). In vitro antiviral activity: S. F. Innaimo et al, Antimicrob. Agents Chemother. 41, 1444 (1997). Review of pharmacology and clinical experience: P. Honkoop, R. A. de Man, Expert Opin. Invest. Drugs 12, 683-688 (2003); T. Shaw, S. Locarnini, Expert Rev. Anti Infect. Ther. 2, 853-871 (2004). Clinical comparisons with lamivudine in chronic hepatitis B: T.-T. Chang et al., N. Engl. J. Med. 354, 1001 (2006); C.-L. Lai et al., ibid. 1011. Derivative Type: Monohydrate CAS Registry Number: 209216-23-9 Manufacturers' Codes: BMS-200475; SQ-200475 Trademarks: Baraclude (BMS) Molecular Formula: C12H15N5O3.H2O Molecular Weight: 295.29 Percent Composition: C 48.81%, H 5.80%, N 23.72%, O 21.67% Properties: White to off-white powder, mp >220¡ã. [a]D +35.0¡ã (c = 0.38 in water). Soly in water: 2.4 mg/ml. pH of saturated soln in water is 7.9 at 25¡ã¡À0.5¡ã. Melting point: mp >220¡ã Optical Rotation: [a]D +35.0¡ã (c = 0.38 in water) Therap-Cat: Antiviral. Keywords: Antiviral; Purines/Pyrimidinones. |

7Â¥2012-02-21 13:21:11
Ñà×Ó·ÉïÚ
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 43 (СѧÉú)
- ½ð±Ò: 569.3
- ºì»¨: 1
- Ìû×Ó: 416
- ÔÚÏß: 29.9Сʱ
- ³æºÅ: 1201413
- ×¢²á: 2011-02-11
- ÐÔ±ð: GG
- רҵ: É«Æ×·ÖÎö

2Â¥2012-02-21 11:13:47
hardee
Ìú¸Ëľ³æ (ÖªÃû×÷¼Ò)
´Ë²ÝÓÐÖ÷~
- DRDEPI: 12
- Ó¦Öú: 152 (¸ßÖÐÉú)
- ¹ó±ö: 0.03
- ½ð±Ò: 10929.3
- É¢½ð: 5544
- ºì»¨: 49
- ɳ·¢: 40
- Ìû×Ó: 6865
- ÔÚÏß: 2905.6Сʱ
- ³æºÅ: 891544
- ×¢²á: 2009-11-02
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ

3Â¥2012-02-21 11:45:39
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
´ÓÍ·¿ªÊ¼(½ð±Ò+1): ¸Ðл²ÎÓë 2012-02-21 12:07:32
yanzhang722(½ð±Ò+5): ¡ïÓаïÖú 2012-02-24 08:42:59
´ÓÍ·¿ªÊ¼(½ð±Ò+1): ¸Ðл²ÎÓë 2012-02-21 12:07:32
yanzhang722(½ð±Ò+5): ¡ïÓаïÖú 2012-02-24 08:42:59
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
4Â¥2012-02-21 11:50:02













»Ø¸´´ËÂ¥